Paper Details

  1. Home
  2. Paper Details

Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.

Author: , ClericiMaurizia, CognettiFrancesco, CrinòLucio, FossatiRoldano, GiacconeGiuseppe, MartelliMassimo, ScagliottiGiorgio V, SilvanoGiovanni, TonatoMaurizio, TorriValter

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the role of adjuvant chemotherapy in patients with completely resected stage I, II, or IIIA non-small-cell lung cancer (NSCLC). The study found no statistically significant difference in overall survival or progression-free survival between patients who received adjuvant chemotherapy (MVP) and those who did not. Only 69% of patients in the MVP group received the planned three cycles of chemotherapy.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Surgery is the primary treatment for patients with stage I, II, or IIIA non-small-cell lung cancer (NSCLC). However, long-term survival of NSCLC patients after surgery alone is largely unsatisfactory, and the role of adjuvant chemotherapy in patient survival has not yet been established....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jnci/djg059

データ提供：米国国立医学図書館（NLM）

Exploring the Shifting Sands of Adjuvant Chemotherapy for Lung Cancer

The treatment of non-small cell lung cancer (NSCLC) is a complex and evolving landscape. This research explores the role of adjuvant chemotherapy, administered after surgery, in improving the long-term survival of patients with stage I, II, or IIIA NSCLC. The authors conducted a randomized trial comparing the efficacy of adjuvant chemotherapy with no treatment, seeking to determine if chemotherapy could significantly impact survival outcomes. Their findings revealed that, in this particular trial, adjuvant chemotherapy did not provide a statistically significant benefit in terms of overall survival or progression-free survival.

Navigating the Uncertainty of Adjuvant Chemotherapy

This research highlights the complexities of adjuvant chemotherapy in NSCLC. While the study did not demonstrate a significant survival benefit in this specific regimen, it emphasizes the need for further investigation into more effective treatment strategies. The authors also point to the importance of exploring alternative chemotherapy regimens and optimizing treatment protocols to improve patient outcomes.

Implications for Lung Cancer Treatment

For patients with NSCLC, this research underscores the importance of personalized treatment decisions. While adjuvant chemotherapy may not be universally beneficial, careful consideration of individual factors, such as disease stage and patient characteristics, is crucial. Ongoing research and collaboration between healthcare providers and patients are essential for developing and implementing the most effective treatment strategies.

Dr. Camel's Conclusion

The desert of lung cancer treatment is vast and complex, requiring a constant search for new and effective strategies. This research reminds us that the journey towards better outcomes is ongoing, driven by rigorous scientific inquiry and a dedication to improving the lives of patients facing this challenging disease. Just as a desert explorer navigates unknown terrain, we must continue to explore new pathways and seek answers to the complexities of lung cancer.

Date :
  1. Date Completed 2003-10-10
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

14519751

DOI: Digital Object Identifier

10.1093/jnci/djg059

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.